Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 155

1.

Are nuchal translucency, pregnancy associated plasma protein-A or free-beta-human chorionic gonadotropin depending on maternal age? A multicenter study of 8,116 pregnancies.

Schmidt P, Pruggmayer M, Steinborn A, Schippert C, Staboulidou I, Hillemanns P, Scharf A.

Arch Gynecol Obstet. 2007 Sep;276(3):259-62. Epub 2007 Mar 7.

PMID:
17342495
2.

Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.

Kagan KO, Wright D, Baker A, Sahota D, Nicolaides KH.

Ultrasound Obstet Gynecol. 2008 Jun;31(6):618-24. doi: 10.1002/uog.5331.

3.

If nuchal translucency screening is combined with first-trimester serum screening the need for fetal karyotyping decreases.

Marsk A, Grunewald C, Saltvedt S, Valentin L, Almström H.

Acta Obstet Gynecol Scand. 2006;85(5):534-8.

PMID:
16752230
4.

Screening for trisomy 18 by maternal age, fetal nuchal translucency, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.

Kagan KO, Wright D, Maiz N, Pandeva I, Nicolaides KH.

Ultrasound Obstet Gynecol. 2008 Sep;32(4):488-92. doi: 10.1002/uog.6123.

5.

First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial).

Dugoff L, Hobbins JC, Malone FD, Porter TF, Luthy D, Comstock CH, Hankins G, Berkowitz RL, Merkatz I, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, Vidaver J, D'Alton ME.

Am J Obstet Gynecol. 2004 Oct;191(4):1446-51.

PMID:
15507981
6.

[Evaluation of pregnancy-associated plasma protein A (PAPP-A) and free beta subunit of human chorionic gonadotropin (beta hCG) levels and sonographic assesement of fetal nuchal translucency (NT) in singleton pregnancies between 11 and 14 weeks of gestation--Polish multi-centre research].

Borowski D, Czuba B, Cnota W, Hincz P, Czekierdowski A, Gajewska J, Jaczyńska R, Ceran A, Włoch A, Wyrwas D, Wiełgoś M, Szymusik I, Szaflik K, Sodowski K.

Ginekol Pol. 2007 May;78(5):384-7. Polish.

PMID:
17867331
7.

First trimester predictors of adverse pregnancy outcomes.

Brameld KJ, Dickinson JE, O'Leary P, Bower C, Goldblatt J, Hewitt B, Murch A, Stock R.

Aust N Z J Obstet Gynaecol. 2008 Dec;48(6):529-35. doi: 10.1111/j.1479-828X.2008.00912.x.

PMID:
19133038
8.

Frontomaxillary facial angle in screening for trisomy 21 at 11 + 0 to 13 + 6 weeks.

Borenstein M, Persico N, Kagan KO, Gazzoni A, Nicolaides KH.

Ultrasound Obstet Gynecol. 2008 Jul;32(1):5-11. doi: 10.1002/uog.5334.

9.

Advanced first trimester screening (AFS): an improved test strategy for the individual risk assessment of fetal aneuploidies and malformations.

Schmidt P, Rom J, Maul H, Vaske B, Hillemanns P, Scharf A.

Arch Gynecol Obstet. 2007 Aug;276(2):159-66.

PMID:
17342500
10.

Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free beta-hCG and pregnancy-associated plasma protein-A.

Kagan KO, Wright D, Valencia C, Maiz N, Nicolaides KH.

Hum Reprod. 2008 Sep;23(9):1968-75. doi: 10.1093/humrep/den224. Epub 2008 Jun 10.

11.

[The prenatal detection of trisomy 13, 18, and 21: comparison of the advanced first trimester screening (AFS) with the first trimester screening according to Nicolaides].

Hörmansdörfer C, Schmidt P, Hillemanns P, Scharf A.

Z Geburtshilfe Neonatol. 2007 Dec;211(6):243-9. doi: 10.1055/s-2007-981361. German.

PMID:
18176905
12.

[Three-dimensional scatter plot analysis to estimate the risk of foetal aneuloidy].

Schmidt P, Hörmansdörfer C, Oehler K, Härtel H, Hillemanns P, Scharf A.

Z Geburtshilfe Neonatol. 2008 Aug;212(4):127-35. doi: 10.1055/s-2008-1004708. German.

PMID:
18729035
13.

Improved prenatal aneuploidy screening using the novel advanced first-trimester screening algorithm: a multicenter study of 10,017 pregnancies.

Schmidt P, Hörmansdörfer C, Pruggmayer M, Schütte C, Neumann A, Gerritzen A, Vaske B, Hillemanns P, Scharf A.

J Clin Ultrasound. 2008 Sep;36(7):397-402. doi: 10.1002/jcu.20509.

PMID:
18626869
14.

First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics.

Kagan KO, Wright D, Spencer K, Molina FS, Nicolaides KH.

Ultrasound Obstet Gynecol. 2008 May;31(5):493-502. doi: 10.1002/uog.5332.

15.

Clinical use of first-trimester aneuploidy screening in a United States population can replicate data from clinical trials.

Perni SC, Predanic M, Kalish RB, Chervenak FA, Chasen ST.

Am J Obstet Gynecol. 2006 Jan;194(1):127-30.

PMID:
16389021
17.

First- and second-trimester screening: detection of aneuploidies other than Down syndrome.

Breathnach FM, Malone FD, Lambert-Messerlian G, Cuckle HS, Porter TF, Nyberg DA, Comstock CH, Saade GR, Berkowitz RL, Klugman S, Dugoff L, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, Tripp T, Bianchi DW, D'Alton ME; First and Second Trimester Evaluation of Risk (FASTER) Research Consortium.

Obstet Gynecol. 2007 Sep;110(3):651-7.

PMID:
17766613
18.
19.

Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities.

Nicolaides KH.

Am J Obstet Gynecol. 2004 Jul;191(1):45-67. Review.

PMID:
15295343
20.

Association of extreme first-trimester free human chorionic gonadotropin-beta, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes.

Krantz D, Goetzl L, Simpson JL, Thom E, Zachary J, Hallahan TW, Silver R, Pergament E, Platt LD, Filkins K, Johnson A, Mahoney M, Hogge WA, Wilson RD, Mohide P, Hershey D, Wapner R; First Trimester Maternal Serum Biochemistry and Fetal Nuchal Translucency Screening (BUN) Study Group.

Am J Obstet Gynecol. 2004 Oct;191(4):1452-8.

PMID:
15507982
Items per page

Supplemental Content

Write to the Help Desk